IP Verse

Amylin Pharmaceuticals, Llc opposition analysis

COMPANY ANALYSIS

Patent:

Grant Date:

Sep 13, 2023

Title:

Sustained Release Formulations Using Non-Aqueous Carriers

Oppositions:

Patent:

Grant Date:

May 8, 2019

Title:

Exendin For Treating Diabetes And Reducing Body Weight

Oppositions:

Patent Number	Grant Date	Title	Total Oppositions
EP2341905	Sep 13, 2023	Sustained Release Formulations Using Non-Aqueous Carriers	1
EP2347762	May 8, 2019	Exendin For Treating Diabetes And Reducing Body Weight	2

GENERICS (UK) LTD

INSTONE, TERRY/APPLEYARD LEES IP LLP/READ, HOWARD

INSTONE, TERRY/READ, HOWARD GRAHAM/APPLEYARD LEES IP LLP

Feel free to send us a message here and we will get back to you